drugset / Trial / NCT01691313

Safety and Efficacy of Vanoxerine for Conversion of Atrial Fibrillation or Flutter to Normal Sinus Rhythm

NCT01691313 ↗

Phase 2 Completed 104 enrolled Laguna Pharmaceuticals, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Evaluate the safety and efficacy of a single oral dose of vanoxerine compared to placebo, in a dose modification manner, on the conversion of symptomatic atrial fibrillation (a-fib) or flutter of recent onset to normal sinus rhythm.

Timeline

Start
2012-11
Primary completion
2013-09
Completion
2013-10

Drugs

EvaluationDrugModalityDoseRoute
Subject vanoxerine Small molecule 200 mg Oral
Subject vanoxerine Small molecule 300 mg Oral
Subject vanoxerine Small molecule 400 mg Oral